Introduction
Chronic heart failure (CHF) is a common cardiovascular disease with a significant economic and societal burden. In the last 20 years, significant progress has been made in medical and device treatment of the disease. Yet, long-term prognosis of heart failure patients remains poor and its pathophysiology is incompletely understood.
Endothelial cells play a central role in blood vessel physiology by regulating vessel wall integrity, vasodilatation and blood coagulation. Impairment of their function (endothelial dysfunction) is a hallmark feature of cardiovascular diseases, 1 including heart failure 2 and is considered an early marker of elevated cardiovascular risk. 3 Most studies on endothelial dysfunction in heart failure focused on evaluation of larger vessels such as brachial artery measurement of flowmediated vasodilatation (FMD). [4] [5] [6] Recently, the role of the microvasculature in heart failure gained more attention. 7, 8 Yet, non-invasive and radiation-free methods to evaluate microvascular dysfunction are still scarce. Retinal vessel analysis (RVA) is a new and unique method to evaluate the retinal microcirculation using flicker lightstimulation and high-resolution measurement of retinal vessels. 9 Flicker light-induced retinal dilatation has been found to involve nitric oxide NO signalling and thereby represents a potential new biomarker for microvascular endothelial dysfunction. 10 This article has been handled by our Guest Editor Anthony DeMaria. Our study was designed to test whether retinal microvascular function as measured by flicker light-induced retinal arteriolar dilatation (FID art ) is compromised in stable and compensated heart failure patients compared to a cohort of healthy controls and patients with cardiovascular risk factors without established cardiovascular disease. Secondary objectives included the measurement of additional retinal microvascular parameters and established tests of vascular function (FMD and arterial stiffness) and correlation with heart failurerelevant clinical parameters.
Methods

Study design and protocol
The study is a cross-sectional observational investigation of retinal microvascular function in heart failure patients and controls in one university centre. The study protocol was approved by the local ethics committee (KEK-ZH-No. 2014-0329). All participants provided written informed consent. Three groups of patients were prospectively recruited for the study:
(i) Patients with a diagnosis of CHF according to the 2012 European Society of Cardiology guidelines in currently compensated clinical status and on stable pharmacologic therapy (CHF group). (ii) Patients currently treated for a modifiable cardiovascular risk factor (hypertension, dyslipidaemia, smoking, and/or diabetes) without any known or symptomatic cardiovascular disease (CVRF group). (iii) Healthy controls as defined by non-smoking volunteers, aged 35 years and older, without any known cardiovascular risk factor or any symptomatic or known cardiovascular disease (HC group). Exclusion criteria were pregnancy or breastfeeding, allergy against study drugs, photosensitive epilepsy, glaucoma, or other significant eye pathologies such as blindness, inability to fixate, progressive diabetic retinopathy, or prior retinal laser coagulation.
After signing informed consent, participants were invited to the main study visit which was conducted in the morning and included a medical history, measurement of clinical and laboratory parameters as well as vascular function tests (vascular stiffness and RVA followed by flowmediated vasodilatation at the end of the examination). Patients were instructed to remain fasted for at least 8 h (except water), take their regular medication as planned (except for antidiabetic medications), refrain from coffee, alcohol and cigarette consumption for at least 12 h, avoid unusual exercise the day before the examination and only present in stable medical state (i.e. free of infections or acute illnesses).
Retinal vessel analysis
RVA was conducted with an Imedos Dynamic Retinal Vessel Analyzer (Imedos, Jena, Germany) using a Zeiss FF450 plus fundus camera (Carl Zeiss Meditec AG, Jena, Germany) connected with two charge-coupled device cameras that provide digital images for a computerized vessel analysis software (Imedos, Jena, Germany). Previously established measurement protocols were used for the study. 9, 11 In brief, one eye was randomly selected and mydriasis was induced using 0.5% tropicamide. After 20 min, dynamic RVA was conducted with measurement of retinal arteriolar and venular dilatation after provocation with 12.5 Hz optoelectronic flicker light. This dilatation is majorly mediated by the release of nitric oxide in response to increased oxygen consumption of retinal photosensitive cells and involves neurovascular coupling. 9, 10 Nitric oxide diffuses to vascular smooth muscle cells where it mediates vascular relaxation via activation of guanylate cyclase and increase in cyclic guanosine monophosphate which activates protein kinase G. Analysis was performed on temporal segments of one retinal arteriole and venule 0.5-2 optic disc diameters away from the optic disc. The selected vessel segments had to be sharp, free of branching sites and reflex stripes and supplied at least one branch arteriole to the macula region. The protocol consisted of a 50 s baseline and three 20 s flicker stimulations each followed by a recovery period of 80 s. After acquisition, the results from the three flicker periods were averaged and percent dilatation of arteriole or venule from baseline (FID art and FID ven , respectively) was calculated automatically using the Imedos analysis software ( Figure 1A) . For static RVA, monochromatic 50 fundus photographs were obtained using Visualis and VesselMap 2 software (Imedos, Jena, Germany) and retinal arteries and vein diameters in the area 0.5-1 optic disc diameters distant from the optic disc were added with calculation of the central retinal artery and vein equivalent (CRAE and CRVE; Figure 1B) .
11 CRAE and CRVE are plotted in relative measuring units (mu). Both values were used to calculate the arterio-venous ratio (AVR = CRAE/CRVE).
Flow-mediated vasodilatation
FMD was assessed using established protocols. 3 In brief, arterial diameter of one brachial artery was continuously measured using a 10 MHz linear array transducer (Siemens Acuson X300, Siemens AG) with automatic wall-tracking and analysis software (FMD-Studio, Pisa, Italy). One minute after its application to the lower arm, the blood pressure cuff was inflated 50 mmHg above systolic pressure for 5 min. After release, hyperaemia occurred and the change in arterial diameter was measured for further 10 min. The percent peak dilatation related to the baseline diameter was calculated and depicted as FMD (%). To ascertain endothelialindependent effects, pharmacological peak percent dilatation of the brachial artery was measured 6 min after one dose of sublingual glycerol trinitrate (GTN; Nitrolingual 0.4 mg, Pohl-Boskamp, Germany). The reproducibility of our laboratory's measurements was published.
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Arterial stiffness
Arterial stiffness was assessed by measuring pulse wave velocity (PWV) and augmentation index (AIX) with a SphygmoCor applanation tonometer system (AtCor Medical, Itasca, IL, USA) according to established protocols. 13, 14 Briefly, patients rest in the supine position for 15 min and measurements are taken immediately after brachial blood pressure recording. AIX was measured at the level of the radial artery by obtaining ten high quality pulse wave measurements with automatic calculation of AIX using the manufacturer's proprietary software and after normalizing to a heart rate of 75 beats per minute. PWV (meter/second) was calculated from the pressure wave transit time and distance between carotid and femoral artery according to recent guidelines. 13, 15 Transit time between arterial sites was determined in relation to the R wave of the electrocardiogram.
Echocardiography
Transthoracic echocardiographies were obtained during regular clinical outpatients visits using M-mode, 2D and color Doppler echocardiography by experienced cardiologists according to current guidelines. 16 All parameters were reanalysed by a single-blinded expert operator using stored images. Left-ventricular ejection fraction (LVEF) was calculated from biplane images using the Simpson's method. Right ventricular fractional area change (RVFAC) was defined as the ratio between the difference of the end-diastolic and end-systolic right ventricular areas and the end-diastolic area. The measurements were corrected for body surface area. Systolic pulmonary artery pressure (SPAP) was measured by addition of right atrial (RA) pressure, as determined by evaluation of inferior vena cava diameter and variability, to the right ventricular (RV)-RA peak systolic gradient as measured from the tricuspid regurgitant time-velocity integral.
. 
Laboratory assessments
Blood samples were obtained in the fasted state using heparin plasma vials at the beginning of the study visit and analyzed on the same day at the Institute of Clinical Chemistry, University Hospital Zurich using standard methods. High sensitivity troponin T and NT-proBNP were quantified using electrochemiluminescence-immunoassays and the COBAS8000 autoanalyzer of Roche Diagnostics (Mannheim, Germany). Undetectable values were replaced by half the lower limit of detection.
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Statistical analysis
Statistical analyses were computed with R (Rproject) and JMP 12.1 (SAS Institute, Cary, North Carolina, USA). The difference in FID art between heart failure patients, patients with cardiovascular risk factors and healthy controls represented the primary endpoint of the study. The other vascular measures (FID ven , AVR, CRAE, CRVE, FMD, PWV, and AIX) served as secondary exploratory outcomes. The results are reported as is and after inverse probability weighting to achieve balance between groups. We aimed to carefully characterize our prospectively recruited cohort and reported associations of echocardiographic and laboratory findings with measures of vascular dysfunction. Results are expressed as mean ± standard deviation (SD) for baseline and predicted mean ± standard error (SE) for outcome statistics unless otherwise noted. Sample size was estimated based on data on FID art of healthy controls by Mandecka et al. 18 Estimating a difference of FID art of 1% (SD 2.1) with power of 80% and an alpha error of 5%, a group size of 70 patients was calculated. Differences in baseline characteristics (Supplementary material online, Table S1 ) were tested. Categorical variables were analysed using v 2 test or Fisher's exact test as appropriate. Continuous characteristics were tested with one-way analysis of variance as omnibus and Student's t-test or Welch's test for unequal variances post hoc. Non-normally distributed data were compared using the Wilcoxon test. Normality was assessed visually by quantile-quantile plots. To achieve between-group balance for possible confounders, 19 generalized covariate balancing propensity scores (CBPS, R package) 20 and subsequent inverse probability weights (IPW) were calculated. The covariates patient age, sex, body mass index (BMI), systolic and diastolic blood pressure, heart rate, total cholesterol, and fasting plasma glucose were selected independently of our sample based on published associations with the outcome and consideration of all possibly confounding group differences. 21 As fasting plasma glucose concentration was highly positively skewed (G 1 = 3.32) and leptokurtic (excess kurtosis = 11.1), glucose is coarsened to a binary covariate with the World Health Organization threshold of glucose > 5.6 mmol/L equalling impaired fasting glucose and glucose < _ 5.6 mmol/L corresponding to the category normal fasting glucose. Briefly, the CBPS method estimates propensity scores generalized for multiple groups within the framework of generalized method of moments 22 by modelling group assignment while simultaneously optimizing covariate balancing. Stabilized and standardized IPW are consequently calculated (R, package CBPS). Linear contrasts (R, package multcomp) and robust 'sandwich' SEs were calculated for generalized linear models (R, survey package) based on the weighted design. The P-values of LSDFisher test results are reported. Predicted means are reported in the bar graphs. Linear regression was used to test the association of relevant echocardiographic and laboratory parameters with vascular function parameters. NT-proBNP was linearized by taking the logarithm. To test the influence of covariates on these associations, multiple linear regression analysis was performed as a second step including the propensity score covariates into the model.
Results
Baseline characteristics
Seventy four patients with CHF (mean age 63.5 ± 11.2 years; 32% female), 74 patients with cardiovascular risk factors without cardiovascular disease (CVRF group; mean age 64.1 ± 12.7; 34% female), and 74 healthy controls (HC group; mean age 57.8 ± 14.2 years, 35% female) were eligible and included in the study between January 2015 and September 2016. Their clinical characteristics, laboratory parameters, and concomitant medication are presented in Table 1 . Patients with CHF were symptomatic (median New York Heart Association class II), had a mean LVEF of 37 ± 12.8% and a median NT-proBNP of 706 ng/L (IQR 1161 ng/L) respectively. Patients with CHF were somewhat older, had a higher BMI and a lower diastolic BP compared to healthy controls. They had a higher rate of comorbidities, including smoking, hypertension, dyslipidaemia, and diabetes compared to healthy controls. No significant differences were found for age, hypertension, and dyslipidaemia compared to the patients with CVRF. Clinical characteristics of the CHF group are shown in Table 2 . The aetiology of CHF was ischaemic cardiomyopathy (ICM; n = 34), dilated CM (DCM; n = 26), and other CM (n = 14).
Supplementary material online, Table S1 and Figures S1 (in summary) and Figure S2 (for each covariate) show balance before and after inverse probability weighting, whereas Supplementary material online, Figure S3 shows weighted propensity score overlap.
Retinal vascular function and structure RVA was available for all participants except one healthy control due to intolerance of the camera light. The primary endpoint (FID art ) was 2.3 ± 0.3 and vs. 3.6 ± 0.2%, both P < 0.001 respectively, Table 3 and Figure 2 ). The primary endpoint was significant before and after correction for baseline group imbalance by propensity score analysis with inverse probability weighting (Supplementary mate rial online, Table S2 ).
Results of secondary outcomes are shown in Table 3 and Figure 3 . Similar differences were found for the exploratory endpoint FID ven with significantly lower venular dilatation in response to flicker light in CHF patients compared to healthy controls (P = 0.027; Figure 3A ).
CHF patients with DCM had a significantly higher FID art compared to CHF patients with ICM (mean FID art 1.5 ± 0.3 vs. 0.4 ± 0.2, P = 0.0045; Figure 3B and Table 4 ). There was no significant difference in FID art and FID ven between patients with HFpEF and HFrEF (Supplementary material online, Figure S4) .
In further exploration, although no significant differences in AVR, CRAE, and CRVE were found between the groups (Table 3 and Figure  3C -E), CRVE tended to be higher in CHF patients compared to HC (P = 0.071).
Other measures of vascular function
Both FMD and GTN-mediated vasodilatation of the brachial artery were not significantly different between CHF and CVRF patients as well as healthy controls (mean FMD 5.1 ± 0.3 vs. 5.6 ± 0.4 vs. 6.1 ± 0.7%, P = 0.32 and P = 0.17, respectively; Figure 4A and B). CHF patients had increased arterial stiffness as evidenced by increased PWV compared to healthy controls and patients with CVRF (mean PWV 9.8 ± 0.4 vs. 7.3 ± 0.2 vs. 8.5 ± 0.3 m/s, P < 0.001 and P = 0.001, respectively, Figure 4C ). On the other hand, there were no significant differences in AIX HR75 between CHF patients and CVRF patients and healthy controls ( Figure 4D ).
Associations of vascular with clinical and echocardiographic heart failure parameters
Concerning the relationship between retinal function and structure, there was no significant correlation between FID art and AVR (r = 0.02, P = 0.70). FMD correlated only weakly with FID art (r = 0. 15 Other CM group includes valvular CM (n = 8), heart failure with preserved ejection fraction (n = 4), non-compaction CM (n = 1), chemotherapy-induced CM (n = 1). With regard to laboratory markers related to heart failure and prognosis, FID ven correlated negatively with log-scaled NT-proBNP (r = -0.25, P = 0.04) and high sensitivity troponin T (r = -0.24, P = 0.04) and positively with eGFR CKD-EPI (r = 0.27, P = 0.02; Supplementary material online, Figure S5 ). There was no significant correlation with FID art and NT-proBNP, troponin T or eGFR CKD-EPI (r = -0.1, P = 0.41, r = 0.15, P = 0.19, and r = 0.11, P = 0.33, respectively). Figure 5 depicts the correlations of retinal venular function with echocardiography measurements [on average 72 days (95% confidence interval 41-112 days) apart from each other]. Interestingly, FID ven correlated negatively with SPAP and left atrial volume index (LAVI), a surrogate for chronically elevated left ventricular filling pressure (r = -0.51, P < 0.001 and r = -0.33, P = 0.004, respectively). Both correlations remained significant in the multiple linear regression model including the covariates used in the propensity score, excluding systolic BP due to collinearity with diastolic BP (b = -4.84, P < 0.001 and b = -2.81, P = 0.03, respectively). Weaker correlations were found for FID art with SPAP and LAVI (r = -0.29, P = 0.03 and r = -0.20, P = 0.09 respectively; not significant after multivariate adjustment). There was no significant correlation of FIDart and FIDven with LVEF. No significant correlation between FMD and SPAP, LAVI, and LVEF was found (r = 0.06, P = 0.68; r = -0.07, P = 0.54 and r = -0.04, P = 0.73 respectively).
Discussion
This systematic cross-sectional study on RVA in stable, compensated heart failure patients for the first time showed that CHF is characterized by a profound alteration in retinal microvascular function as evidenced by significantly reduced flicker-light induced dilatation of the arterial (primary endpoint) and venular vessels of the retina compared to controls. In further exploration considering the positive endpoint, retinal vascular responsiveness to flicker light was particularly impaired in patients with ICM compared to those with DCM. In addition, the extent of retinal venular dysfunction in CHF was correlated with echocardiographic markers of left ventricular filling pressures.
Thus, RVA provides a unique window of opportunity to assess the microcirculation in a standardized manner without the use of invasive or radiographic imaging modalities. Of note, the value of static changes in the retinal vasculature in predicting cardiovascular events, most prominently the relationship between retinal arteriole and venule diameters (AVR) has been well studied in larger prospective observational studies. [23] [24] [25] However, less is known about dynamic changes of retinal vessel reactivity in different forms of cardiovascular disease or after therapeutic interventions. Smaller studies indicate reduced arteriolar and venular dilatation in patients with cardiovascular risk factors, i.e. hypertension, hypercholesterolaemia, diabetes, and obesity. 9 We extend the findings to patients with heart failure, showing profoundly impaired retinal dilatation compared to controls, that remained robust after adjustment for cardiovascular risk factors and possible haemodynamic confounders. The results are in line with a smaller preliminary study showing significantly reduced FID art in 16 patients with DCM compared to healthy controls. 26 Interestingly, retinal dilatation was even more profoundly impaired in ICM than in DCM in our study cohort which may be related to the higher systemic atherosclerotic burden in ICM patients compared to DCM. 27 The pathophysiology of reduced flicker dilatation in patients with CHF is presently a matter of investigation. Defects of endothelial NO signalling in CHF are one possible mechanism. NO has been found to be involved in retinal dilatation 10 and, at the same time, endothelial NO production is known to be reduced in heart failure, possible due to inactivation by increased reactive oxygen species. 2 Due to its easy applicability, RVA may in the future be useful in clinical practice to assess risk in the context of cardiovascular prevention 28 and to quantify the effect of vascular targeted heart failure treatments as recommended by the European guidelines. 29 It is possible that such therapies work better in patients with more pronounced endothelial dysfunction and dynamic RVA may be helpful in selecting patients that benefit most from such treatments. In our study, we observed in contrast to previous studies 4,30 no significant difference in FMD, an established measurement of NOmediated vasodilatation of the brachial artery. One possible explanation of this finding might be the compensated clinical status and the baseline medical drug treatment of our patients with CHF. Indeed, FMD is known to be improved by treatment with ACE inhibitors, beta blockers, mineralocorticoid antagonists, or statins. 2, 30 As the CHF patients in our study were well treated with respect to these drugs, FMD in these patients may have already been partially restored. Such restoration by disease-modifying drugs has not yet been shown for retinal FID. Until longitudinal studies are available, this explanation remains speculative and represents a limitation of the present study. We observed only a weak positive correlation between FMD and FID in our cohort, which was in line with a previous report. 31 There is a possibility that mechanisms beyond NO signalling may be involved in retinal microvascular dysfunction in heart failure. For example, there is evidence of close neurovascular coupling in the retina allowing for a regulation of retinal vessels in response to neuronal activation states and metabolic demands. 19 Cognitive impairment and both structural and functional neuronal alterations are common in CHF. 32 Hence, subclinical cellular dysfunction of retinal nerve cells, even without overt retinopathy, may also underlie retinal microvascular dysfunction in CHF. Interestingly, impaired venular FID was associated with echocardiographically measured systolic pulmonary pressures and left atrial volume. Both are indirect markers of elevated left ventricular filling pressures in heart failure. Retinal microvascular dysfunction at the venous side may thus also be a consequence of myocardial and pulmonary stiffening resulting in increased retinal congestion in CHF. This is supported by the predominant correlation with venular dilatation and the tendency of higher baseline venular diameters in CHF patients as measured by CRVE. While the venular microvasculature might reflect high atrial pressure, the lack of association of arteriolar FID with high pulmonary pressures suggests that systemic mechanisms as discussed above are more dominant drivers of retinal dysfunction on the arterial side. An alternative explanation is that both retinal vascular and myocardial dysfunction are mediated by the same pathophysiologic changes, supported by the observation that pulmonary hypertension and diastolic dysfunction are both associated with alterations in NO signalling.
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Limitations
The study has some limitations. Due to the observational nature of the study, unmeasured confounding between CHF patients and controls is possible. The study was powered for FID art and due to the systematic approach of measuring several vascular parameters the study may have been underpowered for detecting changes in secondary exploratory endpoints such as FMD. The CHF study cohort reflected the average distribution of patients in our heart failure outpatient unit, resulting in enrichment of HFrEF patients. Although we noted no significant differences, the study was not powered for meaningful subgroup analyses (such as of HFpEF patients). Future studies need to delineate whether retinal microvascular dysfunction is prevalent in this heart failure subtype, which appears likely as microvascular dysfunction is thought to play an important pathogenic role in HFpEF. 8 Another limitation is the lower rate of diabetes in the risk factor group compared to CHF patients. As we found no significant difference in arteriolar FID between CHF patients with and without diabetes, the observed differences in retinal microvascular dysfunction are likely to be still largely mediated by the presence of heart failure itself rather than the cumulative burden of individual risk factors. The correlation of echocardiographic parameters is hypothesis generating. Echocardiograms were not performed on the same day of the vascular function measurements but collected in clinical routine. However, as LAVI is thought to reflect a slow anatomic change of the left atrium, we are convinced of the consistency of our associations. Finally, our study was cross-sectional and focused on patients with symptomatic but compensated CHF on stable evidence-based therapy. We cannot extend our findings to patients with newly diagnosed, untreated or decompensated heart failure and the temporal longitudinal evolution of microvascular dysfunction in heart failure patients requires further study. Until longitudinal data on the prediction of heart failure outcomes by retinal microvascular dysfunction are available, the clinical applicability of this method is still limited.
Conclusion
In this first systematic study of both dynamic and static RVA in heart failure, CHF patients were characterized by a reduction of retinal microvascular dilatation in response to flicker light. This association remained significant after propensity score-weighted analysis. Impaired retinal vascular function in CHF was correlated with echocardiographic markers of diastolic dysfunction and pulmonary hypertension. Dynamic RVA may be a new and useful parameter for assessing microvascular dysfunction in heart failure. Future studies will need to delineate whether this method is useful for prognosis and prediction of treatment response of disease-modifying therapies.
